Related Experiment Videos
Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy
J M Cruickshank1, J Lewis, V Moore
1Cardiac Department, Wythenshawe Hospital, Manchester, UK.
Insights
Combination therapy and ACE inhibitors are more effective than beta-blockers and calcium antagonists in reversing left ventricular hypertrophy (LVH). Regressing LVH may reduce cardiovascular events.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Research
Background:
- Left ventricular hypertrophy (LVH) is a significant independent risk factor for coronary artery disease.
- Echocardiography and ECG are key diagnostic tools for assessing LVH.
- Antihypertensive therapies aim to manage blood pressure and mitigate cardiovascular risks.
Purpose of the Study:
- To compare the efficacy of different antihypertensive treatments in reversing left ventricular hypertrophy.
- To analyze the impact of combination therapy, ACE inhibitors, beta-blockers, and calcium antagonists on LVH regression.
Main Methods:
- Systematic overview of 104 studies assessing LVH regression via echocardiography.
- Comparison of four main classes of antihypertensive treatments.
- Analysis independent of treatment duration and blood pressure reduction.
Main Results:
- Combination therapy and ACE inhibitors demonstrated significantly greater efficacy in reducing LV mass compared to beta-blockers and calcium antagonists.
- Treatment effectiveness was consistent regardless of treatment duration or the extent of blood pressure reduction.
- Preliminary data suggest a correlation between LVH regression and reduced cardiovascular events.
Conclusions:
- Certain antihypertensive strategies, specifically combination therapy and ACE inhibitors, are superior for reversing LVH.
- Further research is needed to clarify the clinical significance and long-term benefits of LVH regression on cardiovascular outcomes.
Abstract:
Left ventricular hypertrophy (LVH), as assessed by ECG or echocardiography, is a powerful independent coronary risk factor. The present overview of 104 studies sets out to compare the ability of various forms of antihypertensive therapy to reverse LVH as assessed by echocardiography. Most observations involved four classes of treatment--combination therapy, ACE inhibitors, beta-blockers and calcium antagonists (mainly dihydropyridines). The former two therapies were significantly more effective than the latter two in reversing LV mass, independently of length of time on treatment and degree of fall in blood pressure. Possible reasons for these differences are discussed. The clinical significance of these results is unclear although preliminary data indicate that regressing LVH is associated with fewer cardiovascular events.